Eli Lilly & Co. vs. Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc. Common Stock (RNA) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| LLY | RNA | |
|---|---|---|
| Market Cap | $1.02 trillion | $194.15 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | RNA | |
|---|---|---|
| P/E Ratio | 37.73 | — |
| Price / Book | 30.24 | 0.90 |
| Price / Sales | 12.86 | — |
RNA leads on 1 of 1 valuation factors.
Profitability
| LLY | RNA | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | — |
LLY and RNA split the profitability factors evenly.
Dividend
| LLY | RNA | |
|---|---|---|
| Dividend Yield | 0.62% | — |
| Payout Ratio | 23.23 | — |
LLY and RNA split the dividend factors evenly.
Risk & Sentiment
| LLY | RNA | |
|---|---|---|
| Short Interest | 1.29% | 0.00% |
RNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, RNA overview, RNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.